Clinical trial · no report yet · Phase 3
IMpassion 050
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- NCT03726879 ↗
- Completed
- Hoffmann-La Roche
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 4 | |
| X threads | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Breast Cancer
- Interventions
- Atezolizumab; Placebo; Doxorubicin; Cyclophosphamide; Paclitaxel; Trastuzumab; Pertuzumab; Trastuzumab Emtansine
- Arms
- Atezolizumab +ddAC-PacHP · Experimental
- Placebo + ddAC-PacHP · Placebo comparator
- Enrollment
- 454
- Primary outcomes
- Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3)
- pCR in the ITT Population
- Sponsor
- Hoffmann-La Roche with Chugai Pharmaceutical
- Start
- Jan 11, 2019
- Primary completion
- Feb 5, 2021
- Results posted
- Yes
- Registry record
- NCT03726879 · updated Nov 5, 2024
Publications
linked from the registry- Huober J, Barrios CH, Niikura N, Jarzab M, Chang YC, Huggins-Puhalla SL, Pedrini J, Zhukova L, Graupner V, Eiger D, Henschel V, Gochitashvili N, Lambertini C, Restuccia E, Zhang H; IMpassion050 Trial Investigators. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. J Clin Oncol. 2022 Sep 1;40(25):2946-2956. doi: 10.1200/JCO.21.02772. Epub 2022 Jun 28. PubMed 35763704